Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3340-3351

  Beyer, Ines ^a,f   Cao, Hua ^a   Persson, Jonas ^a   Song, Hui ^a   Richter, Maximilian ^a   Feng, Qinghua ^b   Yumul, Roma ^a   Van Rensburg, Ruan ^a   Li, Zongyi ^a   Berenson, Ronald ^c   Carter, Darrick ^c   Roffler, Steve ^e   Drescher, Charles ^d   Lieber, André ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Compliment Corp ^*  (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CLAUDIN 7; CYCLOPHOSPHAMIDE; DESMOGLEIN; DOXORUBICIN; IRINOTECAN; JO 1 ANTIBODY; PACLITAXEL; PHOSPHATE BUFFERED SALINE; PROTEIN ZO1; RECOMBINANT JUNCTION OPENER 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL SPECIFICITY; COLON CANCER; CONTROLLED STUDY; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TUMOR LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM; LEUKOPENIA; LOW DRUG DOSE; LUNG CANCER; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTECTION; PROTEIN BINDING; PROTEIN EXPRESSION; SOLID TUMOR; SPLEEN DISEASE; STOMACH CANCER; THROMBOCYTOPENIA; TIGHT JUNCTION; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DESMOGLEIN 2; DRUG THERAPY, COMBINATION; HUMANS; INTERCELLULAR JUNCTIONS; MICE; MICE, SCID; MICE, TRANSGENIC; RECOMBINANT PROTEINS; VIRAL PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862514374     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3213     Document Type: Article

References (24)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26. (Pubitemid 33653411)
2. Lavin SR, McWhorter TJ, Karasov WH. Mechanistic bases for differences in passive absorption. J Exp Biol 2007;210:2754 -64.
3. Green SK, Karlsson MC, Ravetch JV, Kerbel RS. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res 2002;62:6891-900. (Pubitemid 35424078)
4. Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C. MUC1&z.ast; is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat 2009;118:113-24.
5. Oliveras-Ferraros C, Vazquez-Martin A, Cufi S, Queralt B, Baez L, Guardeno R, et al. Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux) efficacy in KRAS wild-type tumor cells. J Cell Biochem 2011;112:10-29.
6. Biedermann K, Vogelsang H, Becker I, Plaschke S, Siewert JR, Ho fl er H, et al. Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol 2005;207:199-206. (Pubitemid 41404150)
7. Harada H, Iwatsuki K, Ohtsuka M, Han GW, Kaneko F. Abnormal desmoglein expression by squamous cell carcinoma cells. Acta Derm Venereol 1996;76:417-20. (Pubitemid 26398083)
8. Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 2011;17:96-104.
9. Trinh HV, Lesage G, Chennamparampil V, Vollenweider B, Burckhardt CJ, Schauer S, et al. Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection. J Virol 2012;86:1623-37.
10. Wang H, Li Z, Yumul R, Lara S, Hemminki A, Fender P, et al. Multimerization of adenovirus serotype 3 fiber knob domains is required for effi cient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. J Virol 2011;85:6390-402.
11. Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, et al. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res 2011;71:7080-90.
12. Wang H, Beyer I, Persson J, Song H, Li Z, van Rensburg R, et al. A new human DSG2-transgenic mouse model for studying the tropism and pathology of DSG2-interacting adenoviruses. J Virol 2012;86:6286-302.
13. Su YC, Chen BM, Chuang KH, Cheng TL, Roffler SR. Sensitive quanti fication of PEGylated compounds by second-generation antipoly(ethylene glycol) monoclonal antibodies. Bioconjug Chem 2010;21:1264-70.
14. Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, et al. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res 2011;71:7080-90.
15. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010;328:1031-5.
16. Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 2011;6:e16186.
17. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, et al. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 2011;13:40- 8.
18. Knutson KL, Almand B, Dang Y, Disis ML. Neu antigen-negative variants can be generated aftaer neu-specific antibody therapy in neu transgenic mice. Cancer Res 2004;64:1146-51. (Pubitemid 38176922)
19. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008;16:1665-73.
20. Kurzen H, Munzing I, Hartschuh W. Expression of desmosomal proteins in squamous cell carcinomas of the skin. J Cutan Pathol 2003;30:621-30. (Pubitemid 37372350)
21. Ramani VC, Hennings L, Haun RS. Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. BMC Cancer 2008;8:373.
22. Yashiro M, Nishioka N, Hirakawa K. Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer 2006;42:2397-403. (Pubitemid 44307618)
23. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-26. (Pubitemid 44449137)
24. Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 2007;39:2153-60. (Pubitemid 47484287)